Chimeric Therapeutics (ASX: CHM) secures US patent protection for CORE-NK technology - Kalkine Media

Highlights

• Chimeric Therapeutics secures US patent allowance for its groundbreaking CHM 0201 technology, paving the way for advanced NK cell therapy development.
• CHM 0201 demonstrated safety and efficacy in phase 1A clinical trial for blood cancers and solid tumours.
• The patent, expected to be valid till 2039, would position Chimeric for continued advances in the dynamic field of cell-based therapeutics.

Chimeric Therapeutics (ASX:CHM), an Australian player in cell therapy, is delighted to share a major milestone. The United States Patent & Trademark Office has granted allowance for the issuance of a patent application concerning the CHM 0201 (CORE-NK) technology. This pioneering technology is used to produce CHM’s advanced clinical-stage universal NK cell asset, CHM 0201. It is also used in the manufacture of preclinical-stage NK cell assets CHM 0301, CHM 1301, and CHM 2301. The patent is expected to be valid and give protection till 2039.

The patent application 16/614,132, is entitled as “Compositions for Expanding Natural Killer Cells.” Chimeric owns the exclusive global license to develop and commercialise the allowed patent and related patent applications filed in other international territories for oncology, infectious diseases and immune disorders.

CHM 0201 signifies a potentially leading-edge, clinically proven platform for NK cell therapy. As per the March 2022 published data from complete phase 1A clinical trial, the asset has demonstrated its safety and efficacy in addressing both solid tumours and blood cancers.

Image source: Chimeric ppt

Based on the promising results, Chimeric has initiated two additional Phase 1B clinical trials studying CHM 0201 in combination regimens. Further, the company has also begun the development of new next generation NK and CAR NK assets by utilising the CHM 0201 platform.

The allowance of this patent application not only validates the uniqueness and significance of the CHM 0201 technology but also strengthens Chimeric's intellectual property portfolio. The United States is the single largest global market for biopharmaceutical products and the patent positions the company for continued advances in the burgeoning field of cell-based therapeutics.

In response to the accomplishment, CEO and Managing Director of Chimeric, Jennifer Chow, highlighted that the approval of the initial US patent application is a fundamental element in strengthening the company's best-in-class pipeline of allogeneic NK cell assets. 

At the time of writing this article, the share price of CHM was AU$ 0.031 with an uptick of 3.33%.